T Cell Therapy Market Scope And Analysis

Report Code : TIPRE00024331
Category : Life Sciences

Status : Published
No. of Pages : 138

Buy Now

T Cell Therapy Market Scope and Key Players Analysis by 2030

Buy Now

T Cell Therapy Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 2.75 Billion
Market Size by 2030	US$ 9.04 Billion
Global CAGR (2022 - 2030)	16.0%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Modality Research and Commercialized By Therapy Type CAR T-cell Therapy T-cell Receptor-based By Indication Hematologic Malignancies and Solid Tumors
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Immunocore Holdings Plc Legend Biotech Corp Janssen Global Services LLC Gilead Sciences Inc Bristol Myers Squibb Co Bluebird Bio Inc Novartis AG JW Cayman Therapeutics Co Ltd Cartesian Therapeutics Inc

Competitive Landscape and Key Companies:

A few of the prominent players operating in the global T cell therapy market are Immunocore Holdings Plc, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics Inc, and Innovent Biologics Inc. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. The companies implementing various inorganic and organic developments in the global T cell Therapy market. Below are few instance:

In May 2023, Legend Biotech Corporation announced that a Type II variation application was submitted to the European Medicines Agency (EMA) for CARVYKTI based on data from the CARTITUDE-4 study (NCT04181827), which investigates the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy.
In March 2023, JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, has initiated the clinical study of Carteyva (relmacabtagene autoleucel injection) for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.
In June 2022, The U.S. Food and Drug Administration (FDA) approved Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.